AVGO vs. LLY: Broadcom vs. Eli Lilly Stock Comparison

Company Profile

Broadcom (AVGO) is classified in the Information Technology sector (Semiconductors & Semiconductor Equipment), whereas Eli Lilly (LLY) belongs to Health Care (Pharmaceuticals, Biotechnology & Life Sciences) — their GICS classifications point to very different parts of the market.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Broadcom (AVGO) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.50 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Broadcom (AVGO) at 37.28% and Eli Lilly (LLY) at 102.29% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Eli Lilly (LLY) at 33.53% keeps the most of each sales dollar — above its industry’s net margin range — and Broadcom (AVGO) at 38.85% also retains a top-quartile share.

Both Broadcom (AVGO) at 48.99% and Eli Lilly (LLY) at 54.22% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Broadcom (AVGO) at 23.87% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both companies show strong earnings momentum, but Broadcom (AVGO) at 287.80% is the standout with EPS growth above its industry range; Eli Lilly (LLY) at 95.99% also sits in the top quartile.

Growth Metrics

Financial Strength

Both Broadcom (AVGO) at 2.24 and Eli Lilly (LLY) at 1.36 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Broadcom (AVGO) at 0.74 and Eli Lilly (LLY) at 1.62 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Broadcom (AVGO) at 0.60% earns its spot in the top quartile of its industry’s yields; Eli Lilly (LLY) at 0.54% is past the top of its own peer range — territory where a dividend-safety check matters more than the headline number.

Both pay out more than their industries’ typical bands, and LLY more so: Broadcom (AVGO) at 41.26% sits above the band, while Eli Lilly (LLY) at 21.69% exceeds every peer in its group.

Dividend Metrics

Valuation

Both Broadcom (AVGO) at 69.90 and Eli Lilly (LLY) at 40.00 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Eli Lilly (LLY) at 13.27 is priced about in line with its industry on P/S ratio, while Broadcom (AVGO) at 26.97 sits in the pricier quartile — AVGO costs more per dollar of sales.

Both look rich against book: Broadcom (AVGO) at 23.21 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 33.96 prices even higher, above its industry range.

Valuation Metrics